Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Dara Khosrowshahi steps down from Grab Holdings board
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
Evofem Biosciences (EVFM) Reports Q2 Loss of $1.11
August 2, 2018 7:51 AM EDTEvofem Biosciences (NASDAQ: EVFM) reported Q2 EPS of ($1.11), versus ($0.48) reported last year.
Second Quarter Financial Results and Recent Highlights:
Significant numbers of women completed the 6-month treatment phase of our fully enrolled, confirmatory, Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy (AMP002). With the study continuing to move ahead of schedule, the Company now expects to report top-line results in late 2018.Received positive early findings from a market... More